The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC)
has been hampered by the heterogeneous results from different studies. We aimed to assess the prognostic value of
ctDNA in patients with operable (non metastatic) BC.This work was supported by Lombardy Region Italy [grant
agreement number RR33] as part of the project ‘I controlli
periodici (follow-up) dopo la diagnosi e le terapie in pazienti
liberi da malattia e asintomatici: verso una person-
alizzazione delle strategie di follow-up’.Medicin
